Abstract
Objective - Thrombin signaling promotes atherosclerosis by initiating inflammatory events indirectly through platelet activation and directly via protease-activated receptors. Therefore, endogenous thrombin inhibitors may be relevant modulators of atheroprogression and cardiovascular risk. In addition, endogenous thrombin inhibitors may affect the response to non-vitamin K-dependent oral anticoagulants. Here, the question was addressed whether the small leucine-rich proteoglycan biglycan acts as an endogenous thrombin inhibitor in atherosclerosis through activation of heparin cofactor II. Approach and Results - Biglycan concentrations were elevated in the plasma of patients with acute coronary syndrome and in male Apolipoprotein E-deficient (ApoE-/-) mice. Biglycan was detected in the glycocalyx of capillaries and the subendothelial matrix of arterioles of ApoE-/- mice and in atherosclerotic plaques. Thereby a vascular compartment is provided that may mediate the endothelial and subendothelial activation of heparin cofactor II through biglycan. ApoE and Bgn double-deficient (ApoE-/-/Bgn-/0) mice showed higher activity of circulating thrombin, increased platelet activation and platelet adhesion in vivo, supporting a role of biglycan in balancing thrombin activity. Furthermore, concentrations of circulating cytokines and aortic macrophage content were elevated in ApoE-/-/Bgn-/0 mice, suggesting a proinflammatory phenotype. Elevated platelet activation and macrophage accumulation were reversed by treating ApoE-/-/Bgn-/0 mice with the thrombin inhibitor argatroban. Ultimately, ApoE-/-/Bgn-/0 mice developed aggravated atherosclerosis. Conclusions - The present results indicate that biglycan plays a previously unappreciated protective role during the progression of atherosclerosis by inhibiting thrombin activity, platelet activation, and finally macrophage-mediated plaque inflammation.
| Original language | English |
|---|---|
| Pages (from-to) | e41-e50 |
| Journal | Arteriosclerosis, Thrombosis, and Vascular Biology |
| Volume | 36 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2016 |
Bibliographical note
Publisher Copyright:© 2016 American Heart Association, Inc.
Funding
This work was supported by the Deutsche Forschungsgemeinschaft (IRTG 1902, SFB1116, SFB815, SFB 1039, and SCHA 1082/6-1).
| Funders | Funder number |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | R01HL082772 |
| Deutsche Forschungsgemeinschaft | SCHA 1082/6-1, SFB1116, SFB815, SFB 1039, IRTG 1902 |
Keywords
- atherosclerosis
- biglycan
- blood platelets
- inflammation
- thrombin
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine